Top

Osteoporosis International

Published in:

01-08-2019 | Tenofovir | Letter to the Editor

Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis

Comment on “Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis”

Authors: S. Noe, H. Jaeger, E. Wolf

Published in: Osteoporosis International | Issue 8/2019

Excerpt

With great interest we read the manuscript of the Swiss Association against Osteoporosis on the diagnosis, prevention, and treatment of bone fragility in people living with HIV (PLWH) [1]. This manuscript adds enormously to the care of PLWH, providing the first concise recommendations in this group of people with an excess risk for osteoporosis based on current knowledge [2]. …

Biver E, Calmy A, Aubry-Rozier B, Birkhauser M, Bischoff-Ferrari HA, Ferrari S, Frey D, Kressig RW, Lamy O, Lippuner K, Suhm N, Meier C (2019) Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. Osteoporos Int. https://doi.org/10.1007/s00198-018-4794-0

Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S (2018) Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int 29:595–613CrossRefPubMed

Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S (2017) Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr 75:211–218CrossRefPubMed

Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS (2017) Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>. HIV Clin Trials 18:135–140CrossRefPubMed

Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J, Stein DK, Bellos N, Scarsella A, Yan M, Abram ME, Cheng A, Rhee MS (2017) Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in hiv-infected, virologically suppressed adults. J Acquir Immune Defic Syndr 75:226–231CrossRefPubMedPubMedCentral

Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M (2018) Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV 5:e23–e34CrossRefPubMed

Hill A, Hughes SL, Gotham D, Pozniak AL (2018) Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad 4:72–79PubMedPubMedCentral

Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M (2018) Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet 391:839–849CrossRefPubMed

McComsey GA, Lupo S, Parks D, Poggio MC, De Wet J, Kahl LP, Angelis K, Wynne B, Vandermeulen K, Gartland M, Cupo M, Aboud M (2018) Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. Aids 32:477–485PubMed

10.

Taiwo BO, Chan ES, Fichtenbaum CJ, Ribaudo H, Tsibris A, Klingman KL, Eron JJ, Berzins B, Robertson K, Landay A, Ofotokun I, Brown T (2015) Less bone loss with maraviroc- versus tenofovir-containing antiretroviral therapy in the AIDS clinical trials group A5303 study. Clin Infect Dis 61:1179–1188CrossRefPubMedPubMedCentral

11.

Fabbiani M, Gagliardini R, Ciccarelli N, Quiros Roldan E, Latini A, d’Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Del Pin B, Lombardi F, D’Avino A, Foca E, Colafigli M, Cauda R, Di Giambenedetto S, De Luca A (2018) Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. https://doi.org/10.1093/jac/dky123

12.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K (2019) Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 393:143–155CrossRefPubMed

13.

Moran CA, Weitzmann MN, Ofotokun I (2016) The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS 11:333–342CrossRefPubMedPubMedCentral

14.

Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dube MP, Murphy RL, Stein JH, McComsey GA (2015) Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis 212:1241–1249CrossRefPubMedPubMedCentral

Title: Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis
Comment on “Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis”
Authors: S. Noe
H. Jaeger
E. Wolf
Publication date: 01-08-2019
Publisher: Springer London
Keywords: Tenofovir
Human Immunodeficiency Virus
Osteoporosis
Osteoporosis
Published in: Osteoporosis International / Issue 8/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-05024-4

At a glance: The STEP trials

Springer Medicine

Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis

Comment on “Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis”

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2019

Glucagon-like peptide-1 receptor agonists and fracture risk—limitations to current knowledge

Professor Howard A. Morris

Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis

Patients’ reasons for adhering to long-term alendronate therapy

Dietary inflammatory index® and cortical bone outcomes in healthy adolescent children

Increased risk of osteoporotic vertebral fracture in rheumatoid arthritis patients with new-onset cardiovascular diseases: a retrospective nationwide cohort study in Taiwan